This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cotrim, A. P. Articles by Baum, B. J. Search for Related Content PubMed PubMed Citation Articles by Cotrim, A. P. Articles by Baum, B. J.

Kinetics of Tempol for Prevention of Xerostomia Following Head and Neck Irradiation in a Mouse Model

Authors' Affiliations: ¹ Gene Therapy and Therapeutics Branch and ² Biostatistics Core, Division of Clinical Research and Health Promotion, National Institute of Dental and Craniofacial Research, NIH; and ³ Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland

Requests for reprints: Ana Paola P. Cotrim, Gene Therapy and Therapeutics Branch, National Institute of Dental and Craniofacial Research, NIH, Building 10, Room 1N113, MSC-1190, Bethesda, MD 20892. Phone: 301-451-7956; Fax: 301-402-1228; E-mail: acotrim{at}nidcr.nih.gov.

Purpose: Radiotherapy is commonly used to treat the majority of patients with head and neck cancers. Salivary glands in the radiation field are dramatically affected by this procedure. The purpose of this study was to examine pharmacokinetic characteristics of the stable nitroxide 4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl (tempol) with respect to radioprotection of the salivary glands.

Experimental Design: To evaluate the effect of different doses and times of administration, the heads of C3H mice were exposed to a single irradiation dose of 15 Gy, with i.p. tempol injection. To analyze other routes of administration, we injected 275 mg/kg tempol by an i.m., i.v., or s.c. route, 10 minutes before irradiation. We also tested whether oral administration of tempol in a topical form (either in a mouthwash or gel) provided any salivary gland protection.

Results: Tempol treatment (137.5 or 275 mg/kg, i.p., 10 minutes before irradiation) significantly reduced irradiation-induced salivary hypofunction (50-60%). I.v. or s.c. administration of tempol also showed significant radioprotection, whereas i.m. administration proved to be ineffective. Topical use of tempol, either as a mouthwash or gel, also was radioprotective.

Conclusions: Our results strongly suggest that tempol is a promising candidate for clinical application to protect salivary glands in patients undergoing radiotherapy for head and neck cancers.

This article has been cited by other articles:

				A. P. Cotrim, F. Hyodo, K.-I. Matsumoto, A. L. Sowers, J. A. Cook, B. J. Baum, M. C. Krishna, and J. B. Mitchell Differential Radiation Protection of Salivary Glands versus Tumor by Tempol with Accompanying Tissue Assessment of Tempol by Magnetic Resonance Imaging Clin. Cancer Res., August 15, 2007; 13(16): 4928 - 4933. [Abstract] [Full Text] [PDF]